A carregar...
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse...
Na minha lista:
| Publicado no: | Vasc Health Risk Manag |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762436/ https://ncbi.nlm.nih.gov/pubmed/26937198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S89130 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|